416 related articles for article (PubMed ID: 27997429)
1. Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT "Superscan" in Metastatic Pancreatic Neuroendocrine Tumor.
Chan M; Schembri GP
Clin Nucl Med; 2017 Feb; 42(2):108-109. PubMed ID: 27997429
[TBL] [Abstract][Full Text] [Related]
2. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.
Acar E; Kaya GÇ
Clin Nucl Med; 2019 Jan; 44(1):53-54. PubMed ID: 30325820
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
5. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
6. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Prognostic Value of PET/CT Imaging with Combination of
Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M
Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT and 68Ga-DOTATOC PET/CT in Diffuse Pancreatic Neuroendocrine Tumor.
Ji X; Dong A; He Q; Dong H; Zuo C
Clin Nucl Med; 2020 May; 45(5):e245-e248. PubMed ID: 32049733
[TBL] [Abstract][Full Text] [Related]
9. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
[TBL] [Abstract][Full Text] [Related]
10. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
11. Recurrence of Extramedullary Plasmacytomas Involving Lymph Nodes and Pancreas Revealed by 68Ga-DOTATATE and 18F-FDG PET/CT.
Pan Q; Luo Y; Li J; Zhang S; Li F
Clin Nucl Med; 2018 Dec; 43(12):936-938. PubMed ID: 30179917
[TBL] [Abstract][Full Text] [Related]
12. Clinical role of fludeoxyglucose (18F) positron emission tomography/computed tomography (
Matsumoto T; Okabe H; Yamashita YI; Yusa T; Itoyama R; Nakao Y; Yamao T; Umzaki N; Tsukamoto M; Kitano Y; Miyata T; Arima K; Nitta H; Hayashi H; Imai K; Chikamoto A; Baba H
Surg Today; 2019 Jan; 49(1):21-26. PubMed ID: 30128759
[TBL] [Abstract][Full Text] [Related]
13. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
[TBL] [Abstract][Full Text] [Related]
14. Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors.
You H; Kandathil A; Beg M; De Blanche L; Kazmi S; Subramaniam RM
Nucl Med Commun; 2020 Oct; 41(10):1060-1065. PubMed ID: 32732600
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT.
Ulaner GA; Bodei L
Clin Nucl Med; 2019 Apr; 44(4):330-331. PubMed ID: 30688738
[TBL] [Abstract][Full Text] [Related]
17. Imaging Characteristics of Coexisting Primary Pulmonary Carcinoid Tumor and Multiple Myeloma on 18F-FDG and 68Ga-DOTATATE PET/CT.
Lu Y
Clin Nucl Med; 2019 Nov; 44(11):914-915. PubMed ID: 31306189
[TBL] [Abstract][Full Text] [Related]
18. Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment.
Mapelli P; Partelli S; Salgarello M; Doraku J; Pasetto S; Rancoita PMV; Muffatti F; Bettinardi V; Presotto L; Andreasi V; Gianolli L; Picchio M; Falconi M
Nucl Med Commun; 2020 Sep; 41(9):896-905. PubMed ID: 32796478
[TBL] [Abstract][Full Text] [Related]
19. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.
Cingarlini S; Ortolani S; Salgarello M; Butturini G; Malpaga A; Malfatti V; DʼOnofrio M; Davì MV; Vallerio P; Ruzzenente A; Capelli P; Citton E; Grego E; Trentin C; De Robertis R; Scarpa A; Bassi C; Tortora G
Pancreas; 2017 Jan; 46(1):42-47. PubMed ID: 27906872
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
